Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a 95% mortality rate with no improvement to treatment in decades, and new therapies are desperately needed. PEN-221 is a miniaturized peptide-drug conjugate (∼2 kDa) designed to target SCLC via a Somatostatin Receptor 2 (SSTR2)-targeting ligand and to overcome the high proliferation rate characteristic of this disease by using the potent cytotoxic payload, DM1. SSTR2 is an ideal target for a drug conjugate, as it is overexpressed in SCLC with limited normal tissue expression. In vitro, PEN-221 treatment of SSTR2-positive cells resulted in PEN-221 internalization and receptor-dependent inhibition of cellular proliferation. In vivo, PEN-221 exhibited rapid accumulation in SSTR2-positive SCLC xenograft tumors with quick clearance from plasma. Tumor accumulation was sustained, resulting in durable pharmacodynamic changes throughout the tumor, as evidenced by increases in the mitotic marker of G2-M arrest, phosphohistone H3, and increases in the apoptotic marker, cleaved caspase-3. PEN-221 treatment resulted in significant antitumor activity, including complete regressions in SSTR2-positive SCLC xenograft mouse models. Treatment was effective using a variety of dosing schedules and at doses below the MTD, suggesting flexibility of dosing schedule and potential for a large therapeutic window in the clinic. The unique attributes of the miniaturized drug conjugate allowed for deep tumor penetration and limited plasma exposure that may enable long-term dosing, resulting in durable tumor control. Collectively, these data suggest potential for antitumor activity of PEN-221 in patients with SSTR2-positive SCLC.

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.

Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly internalized upon binding to the receptor and linking a toxic payload to an SSTR2 agonist is a potential method to kill SSTR2-expressing tumor cells. Herein, we describe our efforts towards an efficacious SSTR2-targeting cytotoxic conjugate; examination of different SSTR2-targeting ligands, conjugation sites, and payloads led to the discovery of 22 (PEN-221), a conjugate consisting of microtubule-targeting agent DM1 linked to the C-terminal side chain of Tyr3-octreotate. PEN-221 demonstrates in vitro activity which is both potent (IC50 = 10 nM) and receptor-dependent (IC50 shifts 90-fold upon receptor blockade). PEN-221 targets high levels of DM1 to SSTR2-expressing xenograft tumors, which has led to tumor regressions in several SSTR2-expressing xenograft mouse models. The safety and efficacy of PEN-221 is currently under evaluation in human clinical trials.

Synthesis and molecular and extended structures for a diaminonaphthalene-derived bis(amido)stannylene.

The cyclic bis(amido)tin(II) compound Sn[1,8-((iPrN)2C10H6] (2) was isolated from the reaction of Li2[1,8-((iPrN)2C10H6] (1) and SnCl2. Solid-state structural analysis of 2 showed it to be a mononuclear species with a pyramidal Sn center as part of a nonplanar metallaheterocycle. The packing diagram of 2 revealed an extended one-dimensional head-to-tail chain structure with short intermolecular Sn/arene-C interactions. Computational examination of 2 (DFT/PW91 and MP2 with 6-31G* and 6-311G** basis functions) indicated that the optimum gas-phase structure of 2,which displays a Sn center in the plane of the naphthyl backbone with a slightly twisted metallaheterocycle, is approximately 24 kcal/mol lower in energy than the X-ray structure. The solid-state geometry of 2 is attributed to the intermolecular donation of the naphthalene pi-electrons to a Lewis acidic Sn center, which leads to the observed supramolecular structure. The crystal structure of 1 is also reported.

Constructing a stable carbene with a novel topology and electronic framework.

The perimidine skeleton provides a framework for the isolation of a novel, stable carbene possessing a unique molecular architecture and electronic structure. The remarkable steric environment and exceptional electron-donating ability for the carbene-carbon are revealed through structural and spectroscopic characterization of the parent carbene and two sterically encumbered rhodium-carbene complexes, L2RhCl{C[NCH(CH3)2]2(C10H6)} (5 L2 = COD; 6 L = CO).

Synthesis and structural investigation of N,N',N' '-trialkylguanidinato-supported zirconium(IV) complexes.

The addition of 2 equiv of N,N',N' '-triisopropylguanidine (guanH(2)) to Zr(CH(2)Ph)(4) produced the bis(guanidinato)bis(benzyl)zirconium complex [((i)PrNH)C(N(i)Pr)(2)](2)Zr(CH(2)Ph)(2) (1). The mono(guanidinato) complex [((i)PrN)(2)C(NH(i)Pr)]ZrCl(3) (2) was accessible by the reaction of 2 equiv of guanH(2) with ZrCl(4). Guanidinium hydrochloride, [C(NH(i)Pr)(3)]Cl, is a byproduct of this reaction. When crystallized from THF, complex 2 was isolated as the THF adduct [((i)PrNH)C(N(i)Pr)(2)]ZrCl(3)(THF) (2-THF). The mixed cyclopentadienyl guanidinato complex [eta(5)-1,3-(Me(3)Si)(2)C(5)H(3)][((i)PrNH)C(N(i)Pr)(2)]ZrCl(2) (3) was prepared by treatment of [1,3-(Me(3)Si)(2)C(5)H(3)]ZrCl(3) with the in situ generated lithium triisopropylguanidinate salt. The reaction of guanH(2) with [1,3-(Me(3)Si)(2)C(5)H(3)]ZrMe(3) affords the dimethyl derivative [eta(5)-1,3-(Me(3)Si)(2)C(5)H(3)][((i)PrNH)C(N(i)Pr)(2)]ZrMe(2) (4). Definitive evidence for the molecular structures of these products is provided through single-crystal X-ray characterization of 1, 2-THF, and 3, which are presented. The extent of pi delocalization within the guanidinato ligand is discussed in the context of the metrical parameters obtained from these structural studies.